{
    "clinical_study": {
        "@rank": "119374", 
        "arm_group": {
            "arm_group_label": "FluMist", 
            "arm_group_type": "Experimental", 
            "description": "Subjects receiving vaccine at home"
        }, 
        "brief_summary": {
            "textblock": "This study will examine the feasibility of having parents and caregivers administer FluMist\n      live intranasal vaccine to their children at home outside the traditional medical\n      environment and without the involvement of medical personnel.\n\n      The study will recruit patients and families that are already eligible to receive the\n      FluMist vaccine.  After consent is obtained and vaccine is given to the family, they will go\n      home to administer vaccine to other members within 24 hours.  Telephone follow up within 48\n      hours will confirm that vaccine was given successfully and within 9-12 days to assess\n      patient preferences for giving vaccine at home and if there were any adverse events."
        }, 
        "brief_title": "Home Administration of FluMist by Parents/Caregivers", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The primary caregiver must be 18 years of age or older and willing to give written\n             informed consent for study participation\n\n          2. The primary caregiver must be the parent or legal guardian of all the children in\n             living in the household\n\n          3. All the children in the household who are 2 through 17 years of age must receive\n             their primary care in the clinic\n\n          4. All the children in the household who are 2 through 17 years of age must have private\n             insurance that will provide for the cost of influenza vaccination\n\n          5. There must be at least one  member of the household who is 2 through 17 years of age,\n             presenting for care in the clinic, eligible to receive Live Attenuated Influenza\n             Vaccine (LAIV) and whose primary care giver is willing to administer LAIV to them in\n             the clinic with supervision\n\n          6. There must be at least one family member of the household who is 2 through 17 years\n             of age, not presenting for care in the clinic, eligible to receive LAIV and whose\n             primary care giver is willing to administer LAIV to them in the in-home setting\n\n          7. There must be a working refrigerator in the household\n\n          8. The primary caregiver must have a working telephone number and be willing to be\n             contacted for study follow-up by telephone or e-mail\n\n          9. The primary caregiver is available for the entire study period - 12 days following\n             the last dose of LAIV to be administered to a child\n\n         10. The primary caregiver must agree to complete a 30 minute post vaccination assessment\n             and an 8 day diary following vaccination for each child receiving LAIV.\n\n        Exclusion Criteria:\n\n        1.   Children in the family receive vaccine through Vaccines for Children program"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938170", 
            "org_study_id": "13-2769"
        }, 
        "intervention": {
            "arm_group_label": "FluMist", 
            "description": "Subjects receiving Flumist vaccine", 
            "intervention_name": "FluMist", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "ravi.jhaveri@unc.edu", 
                    "last_name": "Ravi Jhaveri, MD", 
                    "phone": "919-962-5136"
                }, 
                "contact_backup": {
                    "email": "krisav@email.unc.edu", 
                    "last_name": "Kristin Villopoto, RN", 
                    "phone": "919-843-9967"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "University of North Carolina"
                }, 
                "investigator": {
                    "last_name": "Ravi Jhaveri, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "chip.walter@duke.edu", 
                    "last_name": "Emmanuel Walter, MD, MPH", 
                    "phone": "919-620-5333"
                }, 
                "contact_backup": {
                    "email": "lynn.harrington@duke.edu", 
                    "last_name": "Lynn Harrington, RN BSN CCRP", 
                    "phone": "919-620-5353"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University"
                }, 
                "investigator": {
                    "last_name": "Emmanuel Walter, MD, MPH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study to Assess the Acceptability, Tolerability, and Feasibility of Home Intranasal Administration of FluMist\u00ae by a Trained Primary Caregiver to Healthy Family Members 2 Through 17 Years of Age", 
        "overall_contact": {
            "email": "ravi.jhaveri@unc.edu", 
            "last_name": "Ravi Jhaveri, M.D.", 
            "phone": "919-962-5136"
        }, 
        "overall_official": {
            "affiliation": "University of North Carolina", 
            "last_name": "Ravi Jhaveri, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will assess the tolerability of giving the FluMist nasal vaccine at home by parents/caregivers to their children by performing telephone survey follow up.  We will ask parents at both 24-48 hours and at 9-12 days after study visit and enrollment about any difficulties in giving FluMist at home and any adverse events encountered when giving FluMist at home.", 
            "measure": "Number of subjects that reported successful home vaccination with no adverse events", 
            "safety_issue": "No", 
            "time_frame": "0-12 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938170"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "This study will also assess the feasibility of having parents/caregivers administer Flumist vaccine outside a traditional medical environment and without the direct participation of medical personnel.  We will ask parents by telephone survey at both 24-48 hours and at 9-12 days after study visit and enrollment about any difficulties in giving FluMist at home, about maintaining temperature and conditions proper for vaccine storage until administration.  We will also ask about ease of vaccine disposal and about child preferences for receiving vaccine at home compared to at a dedicated medical visit.", 
            "measure": "Number of subjects that reported ability to successfully administer FluMist vaccine at home", 
            "safety_issue": "No", 
            "time_frame": "0-12 days"
        }, 
        "source": "University of North Carolina, Chapel Hill", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of North Carolina", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Duke University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "MedImmune LLC", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of North Carolina, Chapel Hill", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}